Ming-Yuan Chen

Academic / Other · 11 registered clinical trials — 10 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patient Oligo-metastatic Cancer	Phase 3	2026-02-06
Recruiting	Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR- Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	2026-02-06
Recruiting	40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcino Nasopharyngeal Carcinoma	Phase 3	2025-11-20
Recruiting	Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngea Nasopharyngeal Carcinoma (NPC)	Phase 3	2025-11-18
Recruiting	Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Meta Nasopharyngeal Carcinoma (NPC)	Phase 3	2025-08-20
Recruiting	Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive P Recurrent or Metastatic Nasopharyngeal Carcinoma	Phase 2	2025-06-24
Recruiting	Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyng Nasopharyngeal Carcinoma (NPC), Screening, Epstein Barr Virus	N/A	2025-01-24
Active Not Recruiting	"Xijiang Project" Screening Cohort for NPC Nasopharyngeal Carcinoma (NPC), Screening	—	2024-11-14
Recruiting	Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic N Recurrent or Metastatic Nasopharyngeal Carcinoma	Phase 2	2024-07-20
Recruiting	Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Nasopharyngeal Carcinoma, Surgery, Radiotherapy	N/A	2023-11-01
Recruiting	Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnos Nasopharyngeal Carcinoma	N/A	2022-11-01